Toggle navigation
Search
Tree View
MeSH on Demand
MeSH 2024
About
Suggestions
Contact Us
MTOR Inhibitors
MeSH Descriptor Data 2025
Details
Qualifiers
MeSH Tree Structures
Concepts
MeSH Heading
MTOR Inhibitors
Tree Number(s)
D27.505.519.389.755.750
D27.505.696.477.656.625
D27.505.954.248.538
Unique ID
D000091203
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000091203
Scope Note
Agents that inhibit the activity of
TOR SERINE-THREONINE KINASES
.
Entry Term(s)
Rapalogs
Previous Indexing
Protein Kinase Inhibitors(2000-2021)
See Also
TOR Serine-Threonine Kinases
Public MeSH Note
2022
History Note
2022
Date Established
2022/01/01
Date of Entry
2021/07/09
Revision Date
2022/07/14
Allowable Qualifiers
administration & dosage (AD)
adverse effects (AE)
analysis (AN)
blood (BL)
cerebrospinal fluid (CF)
chemical synthesis (CS)
chemistry (CH)
classification (CL)
economics (EC)
history (HI)
immunology (IM)
isolation & purification (IP)
metabolism (ME)
pharmacokinetics (PK)
pharmacology (PD)
poisoning (PO)
radiation effects (RE)
standards (ST)
supply & distribution (SD)
therapeutic use (TU)
toxicity (TO)
urine (UR)
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protein Kinase Inhibitors [D27.505.519.389.755]
Janus Kinase Inhibitors [D27.505.519.389.755.500]
MTOR Inhibitors [D27.505.519.389.755.750]
Tyrosine Kinase Inhibitors [D27.505.519.389.755.875]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Immunologic Factors [D27.505.696.477]
Immunosuppressive Agents [D27.505.696.477.656]
Complement Inactivating Agents [D27.505.696.477.656.500]
Interleukin Inhibitors [D27.505.696.477.656.563]
Interleukin-6 Inhibitors [D27.505.696.477.656.594]
MTOR Inhibitors [D27.505.696.477.656.625]
Myeloablative Agonists [D27.505.696.477.656.750]
Sphingosine 1 Phosphate Receptor Modulators [D27.505.696.477.656.875]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Angiogenesis Inhibitors [D27.505.954.248.025]
Antibiotics, Antineoplastic [D27.505.954.248.106]
Anticarcinogenic Agents [D27.505.954.248.125]
Antimetabolites, Antineoplastic [D27.505.954.248.144]
Antimitotic Agents [D27.505.954.248.147]
Antineoplastic Agents, Alkylating [D27.505.954.248.150]
Antineoplastic Agents, Hormonal [D27.505.954.248.169]
Antineoplastic Agents, Phytogenic [D27.505.954.248.179]
Antineoplastic Agents, Immunological [D27.505.954.248.384]
MTOR Inhibitors [D27.505.954.248.538]
Myeloablative Agonists [D27.505.954.248.589]
Poly(ADP-ribose) Polymerase Inhibitors [D27.505.954.248.692]
Topoisomerase Inhibitors [D27.505.954.248.794]
Expand All
Collapse All
MTOR Inhibitors
Preferred
Concept UI
M000748126
Scope Note
Agents that inhibit the activity of
TOR SERINE-THREONINE KINASES
.
Terms
MTOR Inhibitors
Preferred Term
Term UI
T001106836
Date
05/20/2021
LexicalTag
NON
ThesaurusID
NLM (2022)
Rapalogs
Related
Concept UI
M000748127
Scope Note
A RAPAMYCIN derivative.
Terms
Rapalogs
Preferred Term
Term UI
T001106299
Date
05/12/2021
LexicalTag
TRD
ThesaurusID
NLM (2022)
page delivered in 0.166s